Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma
Authors:
- Jennifer L. KamensJKJennifer L. Kamens
- Jinjun DangJDJinjun Dang
- Timothy I. ShawTSTimothy I. Shaw
- Alexander M. GoutAGAlexander M. Gout
- Scott NewmanSNScott Newman
- Kohei HagiwaraKHKohei Hagiwara
- Amelia M.R. SmithASAmelia M.R. Smith
- Alyssa N. ObermayerAOAlyssa N. Obermayer
- Sarah AldridgeSASarah Aldridge
- Jing MaJMJing Ma
- Yang ZhangYZYang Zhang
- Gang WuGWGang Wu
- 13 January 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (4) , 301-306
Abstract
Myeloid sarcoma is a rare condition consisting of extramedullary myeloid blasts found in association with acute myeloid leukemia or, in the absence of bone marrow involvement. We identified an infant with isolated myeloid sarcoma whose bone marrow was negative for involvement by flow cytometry. Sequencing revealed the fusion oncogene CIC-NUTM2A and identified the sarcoma to be clonally evolved from the bone marrow, which carried the fusion despite the absence of pathology. Murine modeling confirmed the ability of the fusion to transform hematopoietic cells and identified receptor tyrosine kinase (RTK) signaling activation consistent with disruption of the CIC transcriptional repressor. These findings extend the definition of CIC-rearranged malignancies to include hematologic disease, provide insight into the mechanism of oncogenesis, and demonstrate the importance of molecular analysis and tracking of bone marrow involvement over the course of treatment in myeloid sarcoma, including patients that lack flow cytometric evidence of leukemia at diagnosis. Implications: This study illustrates molecular involvement of phenotypically normal bone marrow in myeloid sarcoma, which has significant implications in clinical care. Further, it extends the definition of CIC-rearrangements to include hematologic malignancies and shows evidence of RTK activation that may be exploited therapeutically in cancer(s) driven by these fusions.Keywords
All Related Versions
Funding Information
- American Lebanese Syrian Associated Charities
This publication has 31 references indexed in Scilit:
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- The Pediatric Cancer Genome ProjectNature Genetics, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- The Capicua repressor – a general sensor of RTK signaling in development and diseaseJournal of Cell Science, 2012
- High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1‐negative undifferentiated small blue round cell sarcomasGenes, Chromosomes and Cancer, 2011
- ERK/p90RSK/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicúaBiochemical Journal, 2011
- Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6Blood, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD fingerNature, 2009